G1 Therapeutics

G1 Therapeutics

G1 Therapeutics is a clinical-stage small cap biotechnology company focused on the discovery and development of cancer treatment therapeutics. The company has two distinct clinical-stage selective inhibitors of cyclin-dependent kinases 4/6 (CDK4/6i) in its pipeline, trilaciclib and lerociclib as well as an oral selective estrogen receptor  degrader (SERD). The lead candidate, trilaciclib, is an intravenous CDK4/6 inhibitor that has proven effective in myelopreserving the bone marrow across multiple cell lineages in three clinical trials in small-cell lung cancer. Based on these data, the company is currently submitting the NDA for trilaciclib to the FDA with a potential  approval in mid-2021. The other wholly owned clinical assets, lerociclib and G1T48, are currently in proof-of-concept studies in metastatic breast cancer with relevant newsflow expected over the coming months.